Your browser doesn't support javascript.
loading
Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.
Ding, Ling-Wen; Sun, Qiao-Yang; Tan, Kar-Tong; Chien, Wenwen; Mayakonda, Anand; Yeoh, Allen Eng Juh; Kawamata, Norihiko; Nagata, Yasunobu; Xiao, Jin-Fen; Loh, Xin-Yi; Lin, De-Chen; Garg, Manoj; Jiang, Yan-Yi; Xu, Liang; Lim, Su-Lin; Liu, Li-Zhen; Madan, Vikas; Sanada, Masashi; Fernández, Lucia Torres; Hema Preethi, S S; Lill, Michael; Kantarjian, Hagop M; Kornblau, Steven M; Miyano, Satoru; Liang, Der-Cherng; Ogawa, Seishi; Shih, Lee-Yung; Yang, Henry; Koeffler, H Phillip.
Afiliação
  • Ding LW; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Sun QY; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Tan KT; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Chien W; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Mayakonda A; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Yeoh AEJ; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Kawamata N; Department of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, Duarte, CA, USA.
  • Nagata Y; Division of Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, USA.
  • Xiao JF; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Loh XY; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Lin DC; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Garg M; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Jiang YY; Division of Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, USA.
  • Xu L; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Lim SL; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Liu LZ; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Madan V; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Sanada M; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Fernández LT; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Hema Preethi SS; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Lill M; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Kantarjian HM; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Kornblau SM; Division of Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, USA.
  • Miyano S; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, USA.
  • Liang DC; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, USA.
  • Ogawa S; Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Shih LY; Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Yang H; Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan.
  • Koeffler HP; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Cancer Res ; 77(2): 390-400, 2017 01 15.
Article em En | MEDLINE | ID: mdl-27872090
Current standard of care for patients with pediatric acute lymphoblastic leukemia (ALL) is mainly effective, with high remission rates after treatment. However, the genetic perturbations that give rise to this disease remain largely undefined, limiting the ability to address resistant tumors or develop less toxic targeted therapies. Here, we report the use of next-generation sequencing to interrogate the genetic and pathogenic mechanisms of 240 pediatric ALL cases with their matched remission samples. Commonly mutated genes fell into several categories, including RAS/receptor tyrosine kinases, epigenetic regulators, transcription factors involved in lineage commitment, and the p53/cell-cycle pathway. Unique recurrent mutational hotspots were observed in epigenetic regulators CREBBP (R1446C/H), WHSC1 (E1099K), and the tyrosine kinase FLT3 (K663R, N676K). The mutant WHSC1 was established as a gain-of-function oncogene, while the epigenetic regulator ARID1A and transcription factor CTCF were functionally identified as potential tumor suppressors. Analysis of 28 diagnosis/relapse trio patients plus 10 relapse cases revealed four evolutionary paths and uncovered the ordering of acquisition of mutations in these patients. This study provides a detailed mutational portrait of pediatric ALL and gives insights into the molecular pathogenesis of this disease. Cancer Res; 77(2); 390-400. ©2016 AACR.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Prognostic_studies Limite: Adolescent / Animals / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Prognostic_studies Limite: Adolescent / Animals / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article